We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be... Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. Show more
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION...
As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. 333-260146 UNITED...
As filed with the Securities and Exchange Commission on October 19, 2023 Registration No. 333-208097 Registration No. 333-222003 Registration No. 333-226330 Registration No...
0001641640 false 00-0000000 00000 0001641640 2023-07-30 2023-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares...
0001641640 false 00-0000000 00000 0001641640 2023-07-21 2023-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares...
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | -0.32 | -18.3908045977 | 1.74 | 2.24 | 1.35 | 20487 | 1.56030793 | CS |
156 | -0.33 | -18.8571428571 | 1.75 | 5.75 | 0.1516 | 992413 | 0.97229384 | CS |
260 | -24.28 | -94.4747081712 | 25.7 | 31.9 | 0.1516 | 1703665 | 6.92021126 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions